The Healey-Driscoll Administration recently announced that the Advanced Research Projects Agency for Health (ARPA-H) has awarded new federal funding to the Massachusetts Institute of Technology (MIT), Ropirio Therapeutics, and Seaport Therapeutics to advance innovative health technologies.
MIT was selected for support through ARPA-H’s Ocular Laboratory for Analysis of Biomarkers (OCULAB) program to develop tiny sensors capable of continuously analyzing biomarkers in human tears, enabling real-time health monitoring. Ropirio Therapeutics and Seaport Therapeutics received awards through the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program, which aims to transform treatment of diseases linked to lymphatic dysfunction such as heart disease and autoimmune disorders. Ropirio Therapeutics will create a first-of-its-kind drug that stops lymphatic vessels from leaking and collapsing, a root cause of fluid buildup and chronic swelling, while Seaport Therapeutics will help create an oral therapy that targets lymphatic inflammation, a key driver of central obesity.
“Massachusetts continues to set the national standard as the leading hub for life sciences innovation,” said Massachusetts Life Sciences Center, President and CEO, Kirk Taylor, MD. “These ARPA-H awards underscore the extraordinary strength of our ecosystem and our unmatched ability to translate bold ideas into transformative medical breakthroughs that improve and save the lives of patients around the world.”
Since ARPA-H’s launch, Massachusetts organizations and companies have secured more than $330 million in funding to advance breakthrough health technologies. In 2023, Massachusetts was selected as the location of ARPA-H’s Investor Catalyst Hub, a national center designed to help accelerate the commercialization and scaling of transformative medical innovations.
“Massachusetts continues to set the national standard as the leading hub for life sciences innovation,” said Massachusetts Life Sciences Center, President and CEO, Kirk Taylor, MD. “These ARPA-H awards underscore the extraordinary strength of our ecosystem and our unmatched ability to translate bold ideas into transformative medical breakthroughs that improve and save the lives of patients around the world.”
Since ARPA-H’s launch, Massachusetts organizations and companies have secured more than $330 million in funding to advance breakthrough health technologies. In 2023, Massachusetts was selected as the location of ARPA-H’s Investor Catalyst Hub, a national center designed to help accelerate the commercialization and scaling of transformative medical innovations.
